Last reviewed · How we verify
Placebo matched to fenebrutinib
Placebo matched to fenebrutinib is a Placebo (matched to BTK inhibitor) Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development for Control arm in phase 3 trials for fenebrutinib-targeted indications (likely autoimmune/inflammatory conditions).
This is a placebo control arm matched to fenebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell and myeloid cell activation.
This is a placebo control arm matched to fenebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell and myeloid cell activation. Used for Control arm in phase 3 trials for fenebrutinib-targeted indications (likely autoimmune/inflammatory conditions).
At a glance
| Generic name | Placebo matched to fenebrutinib |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Placebo (matched to BTK inhibitor) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Fenebrutinib inhibits BTK, a key enzyme in B-cell receptor and Toll-like receptor signaling pathways. By blocking BTK, it reduces the activation and proliferation of B cells and other immune cells involved in autoimmune and inflammatory responses. As a placebo matched to fenebrutinib, this arm contains no active drug and serves as a control comparator in clinical trials.
Approved indications
- Control arm in phase 3 trials for fenebrutinib-targeted indications (likely autoimmune/inflammatory conditions)
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (PHASE3)
- Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (PHASE3)
- A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus (PHASE2)
- A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU). (PHASE2)
- Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) (PHASE2)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matched to fenebrutinib CI brief — competitive landscape report
- Placebo matched to fenebrutinib updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Placebo matched to fenebrutinib
What is Placebo matched to fenebrutinib?
How does Placebo matched to fenebrutinib work?
What is Placebo matched to fenebrutinib used for?
Who makes Placebo matched to fenebrutinib?
What drug class is Placebo matched to fenebrutinib in?
What development phase is Placebo matched to fenebrutinib in?
Related
- Drug class: All Placebo (matched to BTK inhibitor) drugs
- Manufacturer: Hoffmann-La Roche — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Control arm in phase 3 trials for fenebrutinib-targeted indications (likely autoimmune/inflammatory conditions)
- Compare: Placebo matched to fenebrutinib vs similar drugs
- Pricing: Placebo matched to fenebrutinib cost, discount & access